Agree. And positive readout figures for PH and Angelman trials may suddenly make 50/sh look a little cheap. Let's not forget the detailed numbers that have been run by some learned folk on our "superior drug"* in terms of potential sales and profits..
If NNZ-2591 proves effective (and PMS trail suggest it will be), and gets market penetration of a Daybue calibre, well, not only will patients and families benefit enormously, but someone is going to make a very, very large pile of money.
*JP's words, not mine.
GLA.
NEU Price at posting:
$18.85 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)